Previous Article | Next Article ![]()
Infection and Immunity, January 2006, p. 425-434, Vol. 74, No. 1
0019-9567/06/$08.00+0 doi:10.1128/IAI.74.1.425-434.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
Nestlé Research Center, CH-1000 Lausanne 26, Switzerland
Received 24 March 2005/ Returned for modification 31 May 2005/ Accepted 13 October 2005
|
|
|---|
|
|
|---|
Lactobacilli are natural inhabitants of the gastrointestinal tract of mammals and are considered potential probiotics. Several probiotics have been demonstrated to enhance gastrointestinal health by stimulation of host immunity and inhibition of pathogen adherence to mucus and epithelial cells (reviewed in references 7 and 44). The ability of lactobacilli to attach to epithelial cells (4, 5, 26, 36, 51) and mucins (27, 34, 43, 48-50)has been documented and is expected to be an important characteristic, enhancing intestinal persistence and antagonistic competition with pathogens, especially at the point of initial contact with the mucosa. Recently, the association of Lactobacillus species with Peyer's patches in mice has been described (40). However, at present, only a few molecules involved in attachment to mucus and to epithelial cells have been identified in Lactobacillus species (16, 42, 45).
Heat shock proteins of the GroEL class, also designated chaperones of the Hsp60 class, are a highly conserved group of proteins essential to all living organisms (19). Their key role consists of mediating protein folding within the cell to guarantee normal function (3, 6). Despite their designation, they are expressed at all temperatures, but basal expression is enhanced by environmental stress, including elevated temperature, oxygen limitation, and nutrient deprivation. From its known functions, the GroEL protein is predicted to be located in the cytoplasm (19), which is supported by the fact that no member of the GroEL family possesses a secretion signal sequence or other recognizable motifs that would suggest its export. However, there are an increasing number of reports indicating an additional extracytoplamic location of GroEL in pathogenic bacteria. Surface-associated Hsp60 has been reported in Mycobacterium leprae (14), Salmonella enterica serovar Typhimurium (9), Clostridium difficile (24), Helicobacter pylori (8, 39, 52), Legionella pneumophila (11), and Haemophilus ducreyi (10). Interestingly, in those mucosal pathogens for which Hsp60 is suggested to be surface exposed, the protein is also implicated in attachment and/or immune modulation activities (8-10, 24, 25, 56, 57).
We report here that, in addition to its cellular functions (55), the Lactobacillus johnsonii La1 GroEL protein can also be found at the bacterial surface and possesses activities that could contribute to its probiotic properties, including attachment to mucus and epithelial cells, stimulation of cytokine secretion in macrophages and epithelial cells, and the ability to mediate aggregation of the gastric pathogen H. pylori.
|
|
|---|
H. pylori strain P1 (20) was grown on 3.6% GC agar plates (Oxoid), supplemented with 1% Isovital (Biological Laboratories) and 10% horse serum (Biological industries) and maintained in a microaerophilic atmosphere (85% N2, 10% CO2, 5% O2) at 37°C for 48 h.
Escherichia coli strains XL1 Blue and BL21(DE3) codon plus RIL were obtained from Stratagene Inc., grown in Luria-Bertani (LB) medium at 37°C with shaking, and supplemented with 50 µg/ml kanamycin and 25 µg/ml chloramphenicol as required. E. coli strain M15(pREP4) was obtained from QIAGEN and grown on LB medium containing 25 µg/ml kanamycin.
Cryocultures of Salmonella enterica serovar Typhimurium strain SL 1344 (kindly provided by B. Stocker, Stanford University, California) and enteropathogenic E. coli strain E 2348/69 (kindly provided by J. Hacker, University of Würzburg, Würzburg, Germany) were grown overnight in 10 ml of LB medium at 37°C with shaking. One hundred microliters of the overnight culture was inoculated into 10 ml of fresh LB medium and grown again at 37°C overnight. The number of bacteria/ml was estimated by measuring the optical density at 600 nm (OD600; 1 OD unit = 1 x 108 bacteria/ml).
Cell culture. Nondifferentiated human adenocarcinoma HT29 cells (American Type Culture Collection) were cultured in glucose-containing Dulbecco's modified Eagle's medium (DMEM) as previously described (31, 53), and HT29-MTX (methotrexate treated) cells were grown according to Lesuffleur (32). Human peripheral blood mononuclear cells were isolated by density centrifugation on Ficoll (Histopaque-1077; Sigma) from fresh blood obtained from healthy donors. Cells were counted and seeded in 96-well Nunclon plates (Nunc) at 2 x 105/well in RPMI 1640 medium (Life Technology) supplemented with 10% endotoxin-free fetal calf serum (Gibco). Monocytes were isolated by adherence to the plastic plates for 2 h at 37°C (29).
Expression of groEL genes in E. coli. The groEL genes of La1 (LJ0461; AE017198), L. helveticus (AF031929), B. subtilis (D10972), and L. lactis (AY029215) were amplified by PCR with specific oligonucleotides containing the appropriate restriction sites for cloning (see Table 1). PCR amplification was performed as described previously (16). The amplicon was digested and ligated into the expression plasmid pET-24d (Novagen), digested with the same restriction enzymes, and transformed into E. coli XL1 Blue. A positive clone was confirmed by DNA sequence analysis and transformed into the expression host BL21(DE3) codon plus RIL.
|
View this table: [in a new window] |
TABLE 1. Primers
used for amplification of groEL genes from different bacteria
|
Purification of recombinant GroEL proteins. Protein expression was induced with 100 µM isopropyl-ß-D-thiogalactopyranoside (IPTG), and the six-His-tagged-fusion proteins were purified under native conditions by Ni2+-nitrilotriacetic acid affinity chromatography (QIAGEN) as described in the manufacturers' protocols. Briefly, bacterial lysates were loaded on a column equilibrated with lysis buffer containing 10 mM imidazole. After being washed with lysis buffer until the eluate reached an OD280 of <0.01, proteins were eluted with a buffer containing 125 mM imidazole. The presence of protein in the different fractions was monitored by the Bio-Rad protein assay. Protein-containing fractions were pooled, equilibrated in phosphate-buffered saline (PBS) by passing through a PD10 column (Amersham), and finally stored at 20°C in the presence of 10% glycerol. Detection of lipopolysaccharide (LPS) contamination of all recombinant proteins was performed with the Limulus amebocyte lysate endochrome test (Charles River Endosafe).
Determination of recombinant La1 GroEL (rGroEL) molecular mass by MALDI-MS. Mass spectrum was recorded on the Autoflex (Bruker) matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS) time-of-flight mass spectrometer operating in the delayed-extraction linear positive-ion mode. Sinapinic acid (saturated solution in 40% acetonitrile containing 0.1% trifluoroacetic acid) was used as a matrix. One microliter of a 50% mix of matrix solution and protein (1 mg/ml) was deposited on the sample holder and allowed to dry at room temperature. External calibration was performed with the protein mixture (Bruker).
La1 rGroEL sequence analysis by nano-ESI-MS (MS/MS). La1 rGroEL protein (1 mg/ml) was dissolved in 50 mM ammonium bicarbonate (Sigma) and digested with 20 ng/µl trypsin (sequencing grade, Promega) or endoproteinase Arg-C (sequencing grade, Roche). The resulting digested peptides were desalted with ZipTip C18 (Millipore) and analyzed by nano-electrospray ionization (nano-ESI)-MS (tandem MS [MS/MS]), as previously described (33). [Glu]-fibrinopeptide MS/MS data were used for mass calibration.
Detection of GroEL at the surface of La1. Detection of GroEL was performed by whole-cell enzyme-linked immunosorbent assay (ELISA). Maxisorb polyvinyl wells (Nunc) were coated with 100 µl of 0.3 x 108 La1/ml in PBS buffer, pH 7.2, overnight at 4°C. After saturation for 1 h at room temperature with 1% bovine serum albumin in PBS buffer, pH 7.2, plates were incubated for 2 h at 4°C with rabbit anti-GroEL (Sigma) or anti-ß-lactoglobulin antibody produced according to a well-described method (23). The antibody concentrations varied from 0.16 to 10.0 µg/ml in PBS-0.05% Tween 20. After three washes with the same buffer, plates were incubated for 1 h at 4°C with horseradish peroxidase (HRP)-conjugated goat anti-rabbit antibody (Zymed) diluted 1/2,000 in PBS-0.05% Tween 20. After three additional washings, HRP enzymatic activity was revealed using the tetramethyl benzidine substrate kit (Pierce) and measured at 450 nm in a Dynatech MR 5000 microtiter plate reader. The supernatant from the first coating with La1 was carefully removed from wells and tested for bacterial lysis by measuring DNA (Ribogreen, quantitation kit; Molecular Probes) and the intracellular marker aldolase (28).
Protein preparation from La1 spent culture medium. La1 was grown as indicated for 2, 4, 6, and 8 h. Spent culture media were recovered by centrifugation at 4,000 x g for 20 min at 4°C. Aliquots of 50 ml were then passed through a 0.2-µm filter, the pH was adjusted to 7.0, and proteins were precipitated by slow addition of ammonium sulfate (Merck) to 60% with gentle shaking. After 30 min of incubation at room temperature, precipitated proteins were recovered by centrifugation at 12,000 x g for 12 min at room temperature and the pellets were suspended in 1 ml of distilled water. Samples were loaded onto a PD10 column (Amersham) equilibrated in PBS. Elution was performed in PBS, and 1-ml fractions were collected and analyzed for protein content (Bio-Rad protein assay, dye reagent). Protein-containing fractions were pooled, divided into aliquots, and frozen at 20°C until further analysis. Protein preparations (20 µg) were loaded onto 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels and transferred onto immunoPVDF (polyvinylidene difluoride) membranes (Bio-Rad), and the presence of GroEL was analyzed by Western blotting using a rabbit anti-GroEL (Sigma) as a primary antibody and a goat anti-rabbit immunoglobulin (Ig) conjugated to alkaline phosphatase (Sigma) as a secondary antibody, both at a dilution of 1/2,000. The alkaline phosphatase enzymatic activity was revealed by the 5-bromo-4-chloro-3-indolylphosphate-nitroblue tetrazolium substrate kit (Zymed) according to the manufacturer's instructions.
Purification of mucin-enriched preparations from HT29-MTX. The cell culture medium of 3-week-old HT29-MTX cells was replaced with serum-free medium for 16 to 24 h. Cell culture supernatants and mucus were collected by repeated gentle pipetting on cells to avoid damaging the monolayer. Mucins were purified by size exclusion chromatography, and the concentration and quality of the preparations were determined as previously described (16).
Assays of binding to mucins and HT29 cells. The capacity of different La1 recombinant proteins to bind to mucins and HT29 cells was tested at pH 7.2 and 5.0 as previously described (16) using 0.1 µg/ml mouse anti-His Tag antibody (Penta. His antibody; QIAGEN) and rabbit anti-mouse Ig-HRP (Zymed) diluted 1/2,000 in PBS-0.05% Tween 20. HRP enzymatic activity was revealed and measured as described above.
La1 binding assays to HT29 cells in the presence of La1 rGroEL. Nondifferentiated HT29 cells (10,000 cells/well) were cultured for 5 days as described previously (16). They were equilibrated in acetate buffer, pH 5.0, and incubated in the same buffer containing 10 mg/ml bovine serum albumin (Sigma) for 30 min at room temperature with serial dilutions of rLa1 GroEL starting at 58 µg/ml (1 nM). La1 bacteria (2.5 x 106 and 5 x 106/well) labeled with 10 µCi of tritiated adenine/ml (17) were added, and this mixture was incubated for 30 min at the same temperature. Bound La1 was determined by radioactivity counting (17).
Measurement of cytokine secretion in HT-29 cells and macrophages. Cytokine secretion in HT-29 cells and macrophages was determined as described previously (16). A 5-day culture of HT29 cells or 2-h-adhered monocytes were washed twice with serum-free medium before the addition of the La1 recombinant proteins, native or heated at 100°C for 20 min, in the presence or absence of 2% human milk (HM) in DMEM. In some wells, MY4, murine anti-CD14 monoclonal antibody (Coulter Instrumentation Laboratory), and/or control mouse IgG2b Igs (Sigma) were also added at a final concentration of 20 µg/ml. Native or heated LPS from E. coli O55:B5 (Sigma) was used as a positive control at different dilutions. Cell viability was determined using a cytotoxicity kit (Roche Diagnostic). Detection of IL-8 release was performed as described previously (53).
Bacterial cell aggregation assays. The aggregation assay was adapted from Ensgraber and Loos (9). Bacteria were harvested and suspended in DMEM adjusted to pH 5.4. The number of bacteria was estimated by measuring the OD600 (1 OD unit = 1 x 108 bacteria/ml). The equivalent of 2.5 x 108 H. pylori, La1, S. enterica serovar Typhimurium, or E. coli cells was added to tubes containing 0, 0.1, 1.0, or 10 µg of H. pylori or La1 rGroEL proteins/ml of DMEM, pH 5.4, and further incubated for 1 h at 37°C. Sedimented bacteria were suspended by manual shaking and then by vortexing for 20 s at maximal speed to dissolve clumps. Ten microliters was loaded on a microscope slide and protected from drying with a coverslip. GroEL-mediated aggregation was assessed by microscopy (BH-2 Olympus) at a magnification of x100 and then photographed.
|
|
|---|
![]() View larger version (19K): [in a new window] |
FIG. 1. (A)
Localization of GroEL at the surface of La1. The presence of GroEL at
the surface of La1 was determined by ELISA as described in Materials
and Methods using a polyclonal anti-GroEL antibody as the primary
antibody (). An anti-ß-lactoglobulin antibody
( ) was used as a negative control. (B) GroEL release
during logarithmic phase growth was monitored by Western blotting in
La1 supernatants after concentration with 60% ammonium sulfate. The
rGroEL protein was used as a positive
control.
|
Characterization of the La1 recombinant GroEL protein. To facilitate the study of the role of La1 GroEL, a recombinant His-tagged La1 GroEL protein was prepared in E. coli. The recombinant protein was analyzed by nano-ESI mass spectrometry. The peptides generated by tryptic digestion of the recombinant La1 protein showed 90% of protein sequence coverage of the predicted sequence, including the C-terminal end containing the six His residues, with no detectable contamination. The N-terminus amino acid was identified as alanine after digestion of the protein by endopeptidase Arg-C (data not shown). All of these results were confirmed by the analysis of the intact protein by MALDI-MS. An ion observed at m/z 59,150 corresponding to the protonated protein indicated a molecular mass of 59,149 Da. The latter result confirmed the molecular mass of the predicted protein, 59,120 Da, and the nano-ESI-MS (MS/MS) analysis.
La1 GroEL binds to mucins and intestinal HT29 cells in a pH-dependent manner. To investigate whether La1 GroEL is implicated in the interactions of bacteria with the gastrointestinal mucosa, two sets of experiments were performed using the recombinant protein in combination with anti-His tag monoclonal antibody detection (Fig. 2). The first set monitored the capacity of La1 GroEL to bind to intestinal mucins. The La1 rGroEL showed strong binding to mucins obtained from HT29-MTX cells at pH 5.0 (Fig. 2A). In contrast, no specific binding was observed when the incubations were performed at pH 7.2 (Fig. 2B). Two other La1 recombinant proteins were tested in parallel in the assay: pyruvate kinase (LJ1080), also detected at the surface of La1 (unpublished results); and the lipoprotein LJ0752, one of the two glutamine ABC transporter solute binding proteins known to be located in the outer membrane of E. coli (13). rLJ1080 showed similar mucin binding capacity at both pHs tested (Fig. 2A and B), but at pH 5.0, the rLJ1080 binding potential was less than 50% of that of rGroEL (Fig. 2A). rLJ0752 did not bind to mucins at either pH (Fig. 2A and B). The latter result excluded the possibility of unspecific binding mediated by the His tag present on the recombinant proteins.
![]() View larger version (19K): [in a new window] |
FIG. 2. Binding
properties of La1 GroEL. The capacity of La1 rGroEL () to bind
mucins (A and B) and to bind to HT29 cells (C and D) was tested at pH
5.0 (A and C) and 7.2 (B and D). Two other La1 recombinant proteins
were tested in parallel: rLJ1080 ( ) and rLJ0752 ( ).
Bound recombinant molecules were revealed using an anti-His tag
antibody. Results are representative of three independent experiments
and are expressed as the mean ± the range of variation
(n =
2).
|
Influence of La1 rGroEL on the binding of La1 to HT29 cells. To determine whether La1 rGroEL was able to interfere with the binding of La1 to cells like intestinal HT29 cells, we performed the binding assays in the presence of increasing amounts of La1 rGroEL. La1 rGroEL induced a decrease of La1 binding from 50 to 35% at concentrations ranging between 0.9 and 3.6 µg/ml, followed by an increase up to 141% at a concentration of 14.4 µg/ml (Fig. 3).
![]() View larger version (13K): [in a new window] |
FIG. 3. La1
binding assays to HT29 cells in the presence of La1 rGroEL.
Nondifferentiated HT29 cells were incubated with increasing
concentrations of La1 rGroEL followed by a second incubation with 2.5
x 106 3H-adenine-labeled La1
bacteria/well. Bound La1 cells were determined by radioactivity
counting. Results are expressed as percentage of binding in the absence
of La1 rGroEL (mean ± standard deviation; n =
6).
|
Bacterial GroEL proteins stimulate IL-8 secretion by isolated blood macrophages. The immunostimulatory capacity of La1 rGroEL was tested in macrophages purified from the blood of healthy donors (Fig. 5). Addition of 1 µg of La1 rGroEL protein resulted in 27- and 19-fold increases in IL-8 secretion in macrophages obtained from two different donors. The increase in IL-8 secretion was on the same order of magnitude as that induced by 1 ng of E. coli LPS used as a positive control. As observed when using HT29 cells, the presence of anti-CD14 antibodies completely blocked the induction of IL-8 secretion in response to either La1 rGroEL or E. coli LPS in macrophages. The immunostimulatory capacity of La1 rGroEL was compared to those of the rGroEL proteins from the three gram-positive bacteria L. helveticus, B. subtilis, and L. lactis and from the gram-negative bacterium H. pylori, after expression in E. coli and purification. Incubation of macrophages with 1 µg of the above rGroEL proteins resulted in an induction of IL-8 secretion similar to that observed with La1 rGroEL (Fig. 5). Addition of anti-CD14 antibodies blocked the induction of IL-8 secretion produced by the rGroEL obtained from gram-positive bacteria but did not alter the H. pylori rGroEL-mediated IL-8 increase. Heat treatment abolished the ability of all rGroEL proteins to induce IL-8, but as expected, it did not affect the stimulation of IL-8 secretion by E. coli LPS, thus indicating once more that the observed activity of the different rGroEL proteins was not due to endotoxin contamination.
![]() View larger version (18K): [in a new window] |
FIG. 5. Stimulation
of IL-8 secretion from macrophages by rGroEL proteins from different
bacteria. Macrophages were isolated from healthy donors as described in
Materials and Methods. IL-8 release was measured by ELISA after
stimulation for 24 h with 1 µg/ml rGroEL proteins
from different bacteria or 1 ng/ml E. coli LPS. Open and solid
bars represent two different donors. Where indicated, cells were
simultaneously treated with anti-CD14 (MY4) or IgG2b antibodies or heat
treated (
|
![]() View larger version (79K): [in a new window] |
FIG. 6. La1
rGroEL aggregating capacity. H. pylori and La1 (A)
as well as S. enterica serovar Typhimurium SL1344 and
E. coli E 2348/69 (B) in DMEM, pH 5.4, were
incubated with no rGroEL as a control, with 0.1 µg of La1
rGroEL/ml, or with 1 µg of H. pylori rGroEL for
1 h at 37°C as indicated to the left of the panels.
After elimination of bacterial clumps by manual shaking and vortexing,
10 µl of the preparation was loaded on a microscope slide and
GroEL-mediated aggregation was assessed under microscope at a
x100 magnification and then
photographed.
|
|
|
|---|
The La1 GroEL was produced in E. coli, and the recombinant protein was used for further functional experiments. The comparison of the sequence and molecular mass of the recombinant protein with those of the predicted protein confirmed authenticity. Our in vitro binding studies suggest that La1 GroEL might contribute to La1 attachment to mucus and/or intestinal cells in the host environment. Binding of rGroEL to mucins or intestinal cell lines was pH dependent: while a strong binding capacity was observed at pH 5.0, no binding occurred at pH 7.2. This is not a unique feature of GroEL. The pH dependency of this process had been observed not only for other mucus binding proteins (45), including La1 EF-Tu (16), but also for the attachment of intact lactobacilli to Caco-2 cells (2, 18). In particular, Blum et al. (2) showed that La1 adhesion to Caco-2 cells was pH dependent and higher at pH 5.0 than at pH 7.2. It has been postulated that the pH of the gut lumen is neutral but becomes gradually more acidic at the mucus-covered surface due to the sialic acid residues and sulfated content of the mucin. Binding at pH 5.0 would thus be more representative of physiological conditions (2). To further study the implication of GroEL in La1 attachment to components of the gastrointestinal mucosa, we performed binding assays to HT29 cells in the presence of La1 rGroEL. La1 rGroEL inhibits the binding of La1 to HT29 cells at concentrations ranging between 0.9 and 3.6 µg/ml but promotes binding at higher concentrations. This increase in binding at a high concentration of rGroEL could be due to "homologous" aggregation of La1 in the presence of intestinal cells, a phenomenon not observed in the absence of intestinal cells. This would be similar to what has been described for S. enterica serovar Typhimurium GroEL, which induces aggregation of the bacterium only in the presence of colonic mucus (9).
Heat shock
proteins from eukaryotic organisms
(29,
30) and gram-negative
bacteria (15,
30,
41,
46) are known to
stimulate macrophages and gastric cells
(56). We demonstrate here
that rGroEL from the gram-positive bacterium L. johnsonii La1
is able to stimulate cytokine secretion in epithelial cells and
macrophages by a CD14-dependent mechanism. Pyruvate kinase (LJ1080),
another surface-exposed La1 protein, showed no stimulation of IL-8
secretion, indicating that this stimulatory property is not common to
all La1 proteins present at the bacterial surface and able to bind to
intestinal cells. All the other rGroEL proteins tested were shown to be
as active as La1 rGroEL in the stimulation of IL-8 secretion from
macrophages. La1 rGroEL, together with the rGroEL obtained from the
three other gram-positive bacteria, exhibited a CD14-dependent
mechanism as already described for human and chlamidial Hsp60
(30). Most of the Hsp60
proteins induce the production of proinflammatory cytokines by the
monocyte-macrophage system via CD14/Toll-like receptor 2 (TLR2) and
CD14/TLR4 receptor complexes leading to activation of NF-
B
(47). Interestingly, we
observed that activation of IL-8 secretion by H. pylori rGroEL
is independent of the presence of CD14, as described for E.
coli GroEL (46).
This in accordance with recent studies showing that H. pylori
GroEL (or Hsp60) stimulates IL-6 secretion from macrophages through a
mechanism that is independent of TLR2, TLR4, and myeloid
differentiation factor 88
(15). In any case, all of
the data obtained concerning the stimulation of IL-8 release by
different rGroEL proteins reinforce previous work suggesting that heat
shock proteins from different organisms may bind to different receptor
complexes (21).
As mentioned before, S. enterica serovar Typhimurium GroEL participates in the aggregation of the bacterium to colonic mucus (9). Actually, we have demonstrated that both a fermented milk containing La1 (38) and a whey-based La1 culture supernatant (35) are able to decrease H. pylori infection levels in humans and also the number of H. pylori cells associated with the human gastric mucosa as determined by biopsy analysis (38). Therefore, we have hypothesized that La1 GroEL, through the aggregation of H. pylori, might contribute to the decrease of bacterial load by facilitating clearance of this pathogen during mucus flushing. We demonstrate in this article that La1 rGroEL does mediate aggregation of the gastric pathogen H. pylori. In contrast to the finding observed with S. enterica serovar Typhimurium GroEL (9), the presence of mucins is not required for the La1 rGroEL-mediated aggregation of H. pylori in vitro (Fig. 6). Furthermore, this effect on H. pylori seems to be specific as La1 rGroEL cannot aggregate the other gram-negative pathogenic bacteria tested, including S. enterica serovar Typhimurium (Fig. 6).
Even though all the gram-positive bacterial rGroEL proteins tested do aggregate H. pylori, we have observed some differences in their aggregation capacities. This may constitute another criterion for the selection of the most suitable probiotic to manage H. pylori infection.
We have shown here that La1 GroEL has a proinflammatory activity and that it is able to aggregate H. pylori cells in vitro. Even though at least two proinflammatory La1 proteins, GroEL and EF-Tu (16), are present at the bacterial surface, intact La1 bacteria do not stimulate IL-8 secretion from intestinal epithelium-like HT29 cells (54) and polarized Caco-2 cells (22) in the presence of sCD14 or peripheral blood mononuclear cells (1) in vitro. The global interpretation could be that the intestinal epithelial cells sense the bacterial surface with its proinflammatory components, like GroEL and EF-Tu, and its anti-inflammatory components, like lipoteichoic acid (53), process the information, and respond with a "consensus" pro- or anti-inflammatory response. In this sense, in vivo shedding of lipoteichoic acid from the La1 surface as a consequence of the stomach's acidic milieu may result in the exposure of the surface-associated proinflammatory molecules, thus favoring the activation of innate defenses. Unfortunately, the available clinical studies with La1where cytokines were measured in biopsies from the gastrointestinal mucosawere performed in patients with chronic inflammation (unpublished data) and therefore do not provide any support for our hypothesis.
We have never observed aggregation of H. pylori cells by intact La1 bacteria in vitro (unpublished results). The maximal amount of GroEL found in the La1 supernatants was 0.15 µg/ml (representing 0.03% of the total GroEL content of the bacterial cell). This amount is not sufficient to induce H. pylori aggregation. In vivo, we have never observed persistent and live La1 cells in the gastric mucosa; therefore, we suggest that the acidic pH of the stomach will concomitantly induce the expression of the stress-sensitive GroEL and increase La1 death. This might finally result in the release of intracellular GroEL in large amounts, thus favoring H. pylori clearance due to its aggregating capacity as shown in vitro in this paper.
In any case, further studies will be required to determine the exact interplay of the La1 surface-exposed molecules within the gastrointestinal environment.
![]() View larger version (18K): [in a new window] |
FIG. 4. Stimulation
of IL-8 secretion from HT29 cells by La1 rGroEL. IL-8 release from HT29
cells was measured by ELISA after stimulation for 24 h with
increasing concentrations of La1 GroEL or LJ1080 recombinant proteins
or E. coli LPS in the absence (open bars) or presence (solid
bars) of 2% HM as a source of sCD14. DMEM with or without HM was used
as a negative control. Where indicated (dotted bars), cells were
simultaneously treated with anti-CD14 (MY4) or IgG2b antibodies or heat
treated (
|
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»